Glaukos Corp (NYSE:GKOS) CFO Joseph E. Gilliam sold 5,000 shares of the firm’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $70.03, for a total value of $350,150.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
NYSE GKOS traded up $0.49 during trading hours on Friday, hitting $68.50. The company had a trading volume of 114,600 shares, compared to its average volume of 243,961. Glaukos Corp has a 52 week low of $26.75 and a 52 week high of $70.91.
Separately, Zacks Investment Research upgraded Glaukos from a “sell” rating to a “hold” rating in a research note on Tuesday, November 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $58.20.
WARNING: “Glaukos Corp (GKOS) CFO Sells $350,150.00 in Stock” was published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/02/22/glaukos-corp-gkos-cfo-sells-350150-00-in-stock.html.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
See Also: How to Trade Using Analysts Ratings
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.